Delivery Order SPE2DB24D2013-SPE2DB24FCHPN

Award Date 9/10/24
Potential Completion Date 9/11/24
Potential Value $61K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $9,274.86 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, for the supply of 180 tablets of the drug ENTRESTO (97 mg-103 mg). This delivery order contract falls under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the agency to efficiently procure a...
The U.S. Defense Logistics Agency (DLA) awarded a $2,736.45 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of ENTRESTO 49 MG-51 MG tablets, a medication used to treat cardiovascular conditions. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC provides...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $2,173.82 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ENTRESTO 49 MG-51 MG TABLET 180S. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $12,161.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 180 tablets of the pharmaceutical product ENTRESTO 24 MG-26 MG. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as...
The U.S. Defense Logistics Agency (DLA) awarded a $1,850.08 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which does not have a set-aside designation, is for the supply of ENTRESTO 24 MG-26 MG TABLET 180S, a cardiovascular medication. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This is a $63,849.99 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ENTRESTO 24 MG-26 MG TABLET 180S. The contract has an ultimate completion date of June 30, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical...
This is a $14,052.75 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, to provide ENTRESTO 24 MG-26 MG tablets. The award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. This...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract (SPE2DX15D3012|SPE2DX24F8LS6) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,148,280 units of the pharmaceutical product ENTRESTO 24 MG-26 MG TABLET 180S. The $17,942.43 contract has an ultimate completion date of April 3, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to...
This is a $3,428.98 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, Corporate Office Division. The contract is for the supply of ENTRESTO 24 MG-26 MG TABLET 180S, a pharmaceutical product, with a period of performance through July 23, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical for providing a comprehensive...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide ENTRESTO 24 MG-26 MG tablets in 180 count bottles. The contract has a ceiling value of $15,425.32 and a performance period through April 15, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through...
  • SPE2DB24D2013
    Indefinite Delivery Contract
  • SPE2DB24D2013-SPE2DB24FCHPN
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $61,266.45 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of the pharmaceutical product ENTRESTO 24 MG-26 MG TABLET 180S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is intended to be completed by September 11, 2024.

Generated 12/10/24, 2:20 PM